1
|
Russell MC, Chang GJ. Molecular profiling for stage II colon cancer. COLORECTAL CANCER 2012. [DOI: 10.2217/crc.12.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
SUMMARY Although nearly 80% of patients with stage II colon cancer are cured by surgery alone, 20% will relapse. One major challenge is to identify individuals who will derive enough benefit from adjuvant therapy to balance the risks, costs and inconvenience. Existing markers, such as microsatellite instability, are predictive and prognostic, but only apply to a small number of patients. Novel technologies that include molecular profiling are emerging tools that may help to identify patients at high risk for recurrence or predict who will derive a greater benefit from adjuvant treatment. This article reviews molecular markers in stage II colon cancer and their potential role in identification of high-risk patients.
Collapse
Affiliation(s)
- Maria C Russell
- Division of Surgical Oncology, Department of Surgery, Emory University Hospital Midtown, 550 Peachtree Street, NE 9th Floor – Ste 9000, Atlanta, GA 30308, USA
| | - George J Chang
- Department of Surgical Oncology, Colorectal Center, University of Texas, MD Anderson Cancer Center, 1400 Pressler Street, FCT 17.6000, Houston, TX 77030, USA
| |
Collapse
|
2
|
|